醫療事務的評價 (歐盟5國) :發炎性疾病的生技仿製藥單株抗體 (生技仿製藥 mAb)
Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders
|醫療事務的評價 (歐盟5國) :發炎性疾病的生技仿製藥單株抗體 (生技仿製藥 mAb) Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders|
|出版日期: 2015年02月01日||內容資訊: 英文||
本報告以英國、法國、德國、西班牙及義大利的150位風濕症醫師、皮膚科醫生，及腸胃科專門醫生為對象所實施的調查結果為基礎，提供企業的醫療事務團隊的生技仿製藥抗TNF單株抗體 (mAb) 的開發與行銷、在各種支援作用中、如何符合醫生需求的相關分析、抗TNF開發企業的醫療事務隊比較分析，為您概述為以下內容。
Based on survey results from 150 rheumatologists, dermatologists, and gastroenterologists in UK, France, Germany, Spain and Italy, ‘Medical Affairs Reputations (EU5): Biosimilar mAbs in Inflammatory Disorders’ offers insights on how Medical Affairs teams from companies developing and marketing biosimilar anti-TNF monoclonal antibodies (mAbs) can best meet physician needs on various supporting roles. In addition, gain comparative insights on the Medical Affairs teams' roles from the originator anti-TNF companies.
Using Need-Gap analysis, a proprietary analytics tool to FirstWord, areas of unmet need are identified, which provide valuable guidance on opportunities for corporate and brand positioning and communication.
With the launch of biosimilar Remicade, and anti-TNF mAb, currently taking place across the major markets of Europe - France, Germany, Italy, Spain, the UK; EU5 - biosimilar mAb developers and companies marketing branded mAbs require solid evidence upon which to base medical affairs' strategy for their products. Refining performance through smarter delivery, higher quality interaction, and effective communication with rheumatologists, dermatologists and gastroenterologists becomes vital for ensuring optimal performance levels of Medical Affairs teams.
Filled with charts and up-to-the-minute survey analysis, this report offers: